This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

U.S. Sees Low Demand for BioCryst Flu Drug

BIRMINGHAM, Ala. ( TheStreet) -- As BioCryst Pharmaceuticals (BCRX - Get Report) seeks to raise money from investors later this week, the U.S. government is seeing light demand so far for the company's antiviral flu drug peramivir.

With evidence emerging that H1N1 flu activity in the U.S. is peaking already, significant additional peramivir orders may not be needed.

A total of 829 treatment courses of peramivir have been shipped from the government's National Strategic Stockpile since the drug was made widely available on Oct. 23, according to Anita Patel, a health scientist working at the Centers for Disease Control and Prevention, the government agency in charge of distributing peramivir to doctors who request it as an emergency treatment for seriously ill H1N1 flu patients.

Patel disclosed the volume of peramivir shipments on a Nov. 13 conference call of the National Biodefense Science Board (NBSB), an advisory group under the auspices of the U.S. Department of Health and Human Services.

The 829 courses of peramivir were used to treat 533 patients, said Patel. Each course of peramivir includes enough drug to dose for five days, so some patients were treated with two courses, or 10 days, of peramivir.

"There's a total of 93% of our [peramivir] supply that remains, so we're confident that the current supply that we have will meet the demands as they've been set forth in the last couple of weeks," said Patel.

BioCryst sold 10,000 courses of peramivir to the U.S. government for $22.5 million on Nov. 5. Another 1,200 doses of the drug were donated. The drug, given intravenously, is still considered experimental and is not approved anywhere in the world.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BCRX $3.24 -5.40%
GSK $43.14 -0.35%
AAPL $95.18 1.64%
FB $117.44 -0.95%
GOOG $692.33 -0.84%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs